Feasibility and Response of Concurrent Weekly Docetaxel with Radical Radiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
Objective: (1) To study the feasibility, adverse effects and response of concurrent weekly Docetaxel with radical radiotherapy in inoperable locally advanced head and neck squamous cell carcinoma. (2) To assess the compliance and tolerance of weekly Docetaxel with radiotherapy. Material and Met...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JCDR Research and Publications Private Limited
2015-03-01
|
| Series: | Journal of Clinical and Diagnostic Research |
| Subjects: | |
| Online Access: | https://jcdr.net/articles/PDF/5614/10819_CE(Ra1)_F(GH)_PF1(PAK)_PFA(AK)_PF2(PAG).pdf |
| Summary: | Objective: (1) To study the feasibility, adverse effects and
response of concurrent weekly Docetaxel with radical radiotherapy
in inoperable locally advanced head and neck squamous cell
carcinoma. (2) To assess the compliance and tolerance of weekly
Docetaxel with radiotherapy.
Material and Methods: Twenty one patients with stage III and IV
head and neck squamous cell carcinoma satisfying inclusion criteria
were selected and treated with conventional external radiotherapy
of 70Gy in 35 fractions with weekly concurrent Docetaxel (15mg/
sqm), administered one hour before radiotherapy. Assessment of
toxicities and evaluationof response was carried out.
Results: Majority of patients had stage IV diseaseand 17/21 (81%)
received the planned radiotherapydose of 70Gy and ≥4 cycles of
weekly chemotherapy. Duration of treatment ranged from 7.1to
11.2 weeks. The toxicities noted were Grade III mucositis in 57%
and grade III skin reaction in 23%, grade III dysphagia in 38%
and grade II weight loss in 23% of patients. Systemic toxicities
associated with chemotherapy were minimal and there was no
dose limiting toxicities. The overall locoregional response at first
follow up was 85%, with complete response of 70% and partial
response of 15%.
Conclusion: Concurrent Docetaxel is a feasible and suitable
alternate to Cisplatin and 5-Fluorouracil chemotherapy with good
patient compliance. The late toxicities and survival need to be
followed up. |
|---|---|
| ISSN: | 2249-782X 0973-709X |